#islatravir

Islatravir, a long-acting antiretroviral, has hit a snag after clinical trial participants experienced falling white blood cell counts.

Studies of islatravir are put on hold after participants experience declining CD4 and lymphocyte counts.

COVID-19, HIV vaccine and cure news, and long-acting HIV treatment and prevention topped the news again this year.

Awareness of the HIV prevention pills don’t match their use.

An islatravir PrEP implant could prevent HIV for a year.

HIV treatment usually requires daily pills, but longer-acting regimens are gaining ground.

Monthly islatravir pills are just one of the long-acting options in the HIV prevention pipeline.

Long-acting antiretrovirals were the big news at CROI this year; now two of the most promising are joining forces.

A next-generation implant maintained adequate drug levels for at least a year in an early study.

Monthly islatravir pills are just one of the long-acting options in the HIV prevention pipeline.

Whether for treatment or prevention, women’s interest in injectable antiretrovirals varied based on their relationship with injection.

The HIV regimen failed only a few study participants.

MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.

The company also has plans to study monthly islatravir’s efficacy as HIV prevention among men who have sex with men.

MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.